Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics

Cancer Treatment Reviews

Volumn 35, Issue 7, 2009, Pages 597-607

  Sarkar, Fazlul H ^a   Li, Yiwei ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer therapy; Cell signaling; Natural products

Indexed keywords

3 INDOLEMETHANOL; 3,3' DIINDOLYLMETHANE; BONISTEIN; CAPECITABINE; CELECOXIB; CURCUMIN; DAIDZEIN; DOCETAXEL; EQUOL; ERLOTINIB; GEMCITABINE; GENISTEIN; GLYCITEIN; GREEN TEA EXTRACT; INTERLEUKIN 2; ISOFLAVONE DERIVATIVE; NATURAL PRODUCT; NOVASOY; PROSTATE SPECIFIC ANTIGEN; QUERCETIN; SOYBEAN PROTEIN; SULINDAC; UNCLASSIFIED DRUG; VENLAFAXINE; VITAMIN D;

ABSENCE OF SIDE EFFECTS; ADENOMATOUS POLYP; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BLADDER CANCER; BOWEN DISEASE; BREAST CANCER; CANCER INHIBITION; CANCER PREVENTION; CANCER THERAPY; CLINICAL TRIAL; COLITIS; COLON CANCER; COLORECTAL ADENOMA; COLORECTAL CANCER; DIET SUPPLEMENTATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; HEAD AND NECK CARCINOMA; HOT FLUSH; HUMAN; INTESTINE METAPLASIA; KIDNEY CANCER; LEUKOPLAKIA; LIVER ADENOMA; LUNG ADENOMA; MELANOMA; METASTASIS INHIBITION; MOUTH CANCER; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NONHUMAN; OSTEOSARCOMA; PANCREAS CANCER; PAPILLOMA; PAPILLOMATOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE TUMOR; RECOMMENDED DRUG DOSE; RECTUM CANCER; REVIEW; RISK REDUCTION; SQUAMOUS CELL CARCINOMA; SYSTEMIC DISEASE; TUMOR RECURRENCE; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; VAGINAL INTRAEPITHELIAL NEOPLASIA;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; CURCUMIN; HUMANS; INDOLES; ISOFLAVONES; NEOPLASMS;

EID: 70350225860     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.07.001     Document Type: Review

References (115)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Lee M.M., Gomez S.L., Chang J.S., Wey M., Wang R.T., and Hsing A.W. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev 12 (2003) 665-668
3. Smith-Warner S.A., Spiegelman D., Yaun S.S., et al. Fruits, vegetables and lung cancer: a pooled analysis of cohort studies. Int J Cancer 107 (2003) 1001-1011
4. Surh Y.J. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3 (2003) 768-780
5. Khan N., Afaq F., and Mukhtar H. Apoptosis by dietary factors: the suicide solution for delaying cancer growth. Carcinogenesis 28 (2007) 233-239
6. Sarkar FH, Li Y, Wang Z, Kong D. Cellular signaling perturbation by natural products. Cell Signal 2009.
7. Sarkar F.H., and Li Y.W. Targeting multiple signal pathways by chemopreventive agents for cancer prevention and therapy. Acta Pharmacol Sin 28 (2007) 1305-1315
8. Hamilton-Reeves J.M., Rebello S.A., Thomas W., Slaton J.W., and Kurzer M.S. Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor-beta expression or serum hormonal profiles in men at high risk of prostate cancer. J Nutr 137 (2007) 1769-1775
9. Pendleton J.M., Tan W.W., Anai S., et al. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer 8 (2008) 132
10. Vaishampayan U., Hussain M., Banerjee M., et al. Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr Cancer 59 (2007) 1-7
11. Bemis D.L., Katz A.E., and Buttyan R. Clinical trials of natural products as chemopreventive agents for prostate cancer. Expert Opin Investig Drugs 15 (2006) 1191-1200
12. Dhillon N., Aggarwal B.B., Newman R.A., et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14 (2008) 4491-4499
13. Naik R., Nixon S., Lopes A., Godfrey K., Hatem M.H., and Monaghan J.M. A randomized phase II trial of indole-3-carbinol in the treatment of vulvar intraepithelial neoplasia. Int J Gynecol Cancer 16 (2006) 786-790
14. Barnes S. The chemopreventive properties of soy isoflavonoids in animal models of breast cancer. Breast Cancer Res Treat 46 (1997) 169-179
15. Dixon R.A., and Genistein F.D. Phytochemistry 60 (2002) 205-211
16. Li Y., and Sarkar F.H. Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. Cancer Lett 186 (2002) 157-164
17. Chinni S.R., Li Y., Upadhyay S., Koppolu P.K., and Sarkar F.H. Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene 20 (2001) 2927-2936
18. Li Y., Li X., and Sarkar F.H. Gene expression profiles of I3C- and DIM-treated PC3 human prostate cancer cells determined by cDNA microarray analysis. J Nutr 133 (2003) 1011-1019
19. Mukhopadhyay A., Bueso-Ramos C., Chatterjee D., Pantazis P., and Aggarwal B.B. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 20 (2001) 7597-7609
20. Shao Z.M., Shen Z.Z., Liu C.H., et al. Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int J Cancer 98 (2002) 234-240
21. Davis J.N., Kucuk O., and Sarkar F.H. Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr Cancer 35 (1999) 167-174
22. Chen C.C., Sun Y.T., Chen J.J., and Chiu K.T. TNF-alpha-induced cyclooxygenase-2 expression in human lung epithelial cells: involvement of the phospholipase C-gamma 2, protein kinase C-alpha, tyrosine kinase, NF-kappa B-inducing kinase, and I-kappa B kinase 1/2 pathway. J Immunol 165 (2000) 2719-2728
23. Natarajan K., Manna S.K., Chaturvedi M.M., and Aggarwal B.B. Protein tyrosine kinase inhibitors block tumor necrosis factor-induced activation of nuclear factor-kappa B, degradation of IkappaBalpha, nuclear translocation of p65, and subsequent gene expression. Arch Biochem Biophys 352 (1998) 59-70
24. Li Y., Ahmed F., Ali S., Philip P.A., Kucuk O., and Sarkar F.H. Inactivation of nuclear factor kappa B by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 65 (2005) 6934-6942
25. Li Y., and Sarkar F.H. Inhibition of nuclear factor kappa B activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 8 (2002) 2369-2377
26. Gong L., Li Y., Nedeljkovic-Kurepa A., and Sarkar F.H. Inactivation of NF-kappa B by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene 22 (2003) 4702-4709
27. Akiyama T., Ishida J., Nakagawa S., et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262 (1987) 5592-5595
28. Li Y., Wang Z., Kong D., Li R., Sarkar S.H., and Sarkar F.H. Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells. J Biol Chem 283 (2008) 27707-27716
29. Su Y., Simmen F.A., Xiao R., and Simmen R.C. Expression profiling of rat mammary epithelial cells reveals candidate signaling pathways in dietary protection from mammary tumors. Physiol Genomics 30 (2007) 8-16
30. Su Y., and Simmen R.C. Soy isoflavone genistein upregulates epithelial adhesion molecule E-cadherin expression and attenuates beta-catenin signaling in mammary epithelial cells. Carcinogenesis 30 (2009) 331-339
31. Wang Z., Zhang Y., Li Y., Banerjee S., Liao J., and Sarkar F.H. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 5 (2006) 483-493
32. Wang Z., Zhang Y., Banerjee S., Li Y., and Sarkar F.H. Inhibition of nuclear factor kappa b activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. Int J Cancer 118 (2006) 1930-1936
33. Davis J.N., Muqim N., Bhuiyan M., Kucuk O., Pienta K.J., and Sarkar F.H. Inhibition of prostate specific antigen expression by genistein in prostate cancer cells. Int J Oncol 16 (2000) 1091-1097
34. Davis J.N., Kucuk O., and Sarkar F.H. Expression of prostate-specific antigen is transcriptionally regulated by genistein in prostate cancer cells. Mol Carcinog 34 (2002) 91-101
35. Fritz W.A., Wang J., Eltoum I.E., and Lamartiniere C.A. Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate. Mol Cell Endocrinol 186 (2002) 89-99
36. Sharma O.P., Adlercreutz H., Strandberg J.D., Zirkin B.R., Coffey D.S., and Ewing L.L. Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. J Steroid Biochem Mol Biol 43 (1992) 557-564
37. Onozawa M., Kawamori T., Baba M., et al. Effects of a soybean isoflavone mixture on carcinogenesis in prostate and seminal vesicles of F344 rats. Jpn J Cancer Res 90 (1999) 393-398
38. Landstrom M., Zhang J.X., Hallmans G., et al. Inhibitory effects of soy and rye diets on the development of Dunning R3327 prostate adenocarcinoma in rats. Prostate 36 (1998) 151-161
39. Zhou J.R., Gugger E.T., Tanaka T., Guo Y., Blackburn G.L., and Clinton S.K. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr 129 (1999) 1628-1635
40. Li D., Yee J.A., McGuire M.H., Murphy P.A., and Yan L. Soybean isoflavones reduce experimental metastasis in mice. J Nutr 129 (1999) 1075-1078
41. Lamartiniere C.A., Moore J.B., Brown N.M., Thompson R., Hardin M.J., and Barnes S. Genistein suppresses mammary cancer in rats. Carcinogenesis 16 (1995) 2833-2840
42. Uckun F.M., Evans W.E., Forsyth C.J., et al. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science 267 (1995) 886-891
43. Wei H., Wei L., Frenkel K., Bowen R., and Barnes S. Inhibition of tumor promoter-induced hydrogen peroxide formation in vitro and in vivo by genistein. Nutr Cancer 20 (1993) 1-12
44. Kameoka S., Leavitt P., Chang C., and Kuo S.M. Expression of antioxidant proteins in human intestinal Caco-2 cells treated with dietary flavonoids. Cancer Lett 146 (1999) 161-167
45. Davis J.N., Kucuk O., Djuric Z., and Sarkar F.H. Soy isoflavone supplementation in healthy men prevents NF-kappa B activation by TNF-alpha in blood lymphocytes. Free Radic Biol Med 30 (2001) 1293-1302
46. Hussain M., Banerjee M., Sarkar F.H., et al. Soy isoflavones in the treatment of prostate cancer. Nutr Cancer 47 (2003) 111-117
47. Pendleton J.M., Tan W.W., Anai S., et al. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer 8 (2008) 132
48. Hamilton-Reeves J.M., Rebello S.A., Thomas W., Slaton J.W., and Kurzer M.S. Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor-beta expression or serum hormonal profiles in men at high risk of prostate cancer. J Nutr 137 (2007) 1769-1775
49. Joniau S., Goeman L., Roskams T., Lerut E., Oyen R., and Van P.H. Effect of nutritional supplement challenge in patients with isolated high-grade prostatic intraepithelial neoplasia. Urology 69 (2007) 1102-1106
50. Kumar N.B., Cantor A., Allen K., et al. The specific role of isoflavones in reducing prostate cancer risk. Prostate 59 (2004) 141-147
51. Vere White R.W., Hackman R.M., Soares S.E., Beckett L.A., Li Y., and Sun B. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology 63 (2004) 259-263
52. Adams K.F., Chen C., Newton K.M., Potter J.D., and Lampe J.W. Soy isoflavones do not modulate prostate-specific antigen concentrations in older men in a randomized controlled trial. Cancer Epidemiol Biomarkers Prev 13 (2004) 644-648
53. Martin P.M., Horwitz K.B., Ryan D.S., and McGuire W.L. Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology 103 (1978) 1860-1867
54. Messina M.J., and Wood C.E. Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary. Nutr J 7 (2008) 17
55. Lampe J.W., Nishino Y., Ray R.M., et al. Plasma isoflavones and fibrocystic breast conditions and breast cancer among women in Shanghai, China. Cancer Epidemiol Biomarkers Prev 16 (2007) 2579-2586
56. Dai Q., Franke A.A., Yu H., et al. Urinary phytoestrogen excretion and breast cancer risk: evaluating potential effect modifiers endogenous estrogens and anthropometrics. Cancer Epidemiol Biomarkers Prev 12 (2003) 497-502
57. Sartippour M.R., Rao J.Y., Apple S., et al. A pilot clinical study of short-term isoflavone supplements in breast cancer patients. Nutr Cancer 49 (2004) 59-65
58. Kumar N.B., Cantor A., Allen K., Riccardi D., and Cox C.E. The specific role of isoflavones on estrogen metabolism in premenopausal women. Cancer 94 (2002) 1166-1174
59. Bobe G., Sansbury L.B., Albert P.S., et al. Dietary flavonoids and colorectal adenoma recurrence in the polyp prevention trial. Cancer Epidemiol Biomarkers Prev 17 (2008) 1344-1353
60. Adams K.F., Lampe P.D., Newton K.M., et al. Soy protein containing isoflavones does not decrease colorectal epithelial cell proliferation in a randomized controlled trial. Am J Clin Nutr 82 (2005) 620-626
61. Ahmad I.U., Forman J.D., Sarkar F., et al. Reduction of adverse events by soy isoflavones in patients undergoing external beam radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 72 (2009) S318
62. Verhoeven D.T., Verhagen H., Goldbohm R.A., van den Brandt P.A., and van P.G. A review of mechanisms underlying anticarcinogenicity by brassica vegetables. Chem Biol Interact 103 (1997) 79-129
63. Dashwood R.H., Fong A.T., Arbogast D.N., Bjeldanes L.F., Hendricks J.D., and Bailey G.S. Anticarcinogenic activity of indole-3-carbinol acid products: ultrasensitive bioassay by trout embryo microinjection. Cancer Res 54 (1994) 3617-3619
64. Bhuiyan M.M., Li Y., Banerjee S., et al. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 66 (2006) 10064-10072
65. Li Y., Chinni S.R., and Sarkar F.H. Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-kappa B pathways in prostate cancer cells. Front Biosci 10 (2005) 236-243
66. Chinni S.R., and Sarkar F.H. Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. Clin Cancer Res 8 (2002) 1228-1236
67. Leong H., Riby J.E., Firestone G.L., and Bjeldanes L.F. Potent ligand-independent estrogen receptor activation by 3,3'-diindolylmethane is mediated by cross talk between the protein kinase A and mitogen-activated protein kinase signaling pathways. Mol Endocrinol 18 (2004) 291-302
68. Li Y., Wang Z., Kong D., et al. Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3, 3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J Biol Chem 282 (2007) 21542-21550
69. Le H.T., Schaldach C.M., Firestone G.L., and Bjeldanes L.F. Plant-derived 3,3′-diindolylmethane is a strong androgen antagonist in human prostate cancer cells. J Biol Chem 278 (2003) 21136-21145
70. Bradlow H.L., Michnovicz J., Telang N.T., and Osborne M.P. Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 12 (1991) 1571-1574
71. Kojima T., Tanaka T., and Mori H. Chemoprevention of spontaneous endometrial cancer in female Donryu rats by dietary indole-3-carbinol. Cancer Res 54 (1994) 1446-1449
72. Manson M.M., Hudson E.A., Ball H.W., et al. Chemoprevention of aflatoxin B1-induced carcinogenesis by indole-3-carbinol in rat liver-predicting the outcome using early biomarkers. Carcinogenesis 19 (1998) 1829-1836
73. Stresser D.M., Bailey G.S., and Williams D.E. Indole-3-carbinol and beta-naphthoflavone induction of aflatoxin B1 metabolism and cytochromes P-450 associated with bioactivation and detoxication of aflatoxin B1 in the rat. Drug Metab Dispos 22 (1994) 383-391
74. Bradfield C.A., and Bjeldanes L.F. Effect of dietary indole-3-carbinol on intestinal and hepatic monooxygenase, glutathione S-transferase and epoxide hydrolase activities in the rat. Food Chem Toxicol 22 (1984) 977-982
75. Souli E., Machluf M., Morgenstern A., Sabo E., and Yannai S. Indole-3-carbinol (I3C) exhibits inhibitory and preventive effects on prostate tumors in mice. Food Chem Toxicol 46 (2008) 863-870
76. Kassie F., Anderson L.B., Scherber R., et al. Indole-3-carbinol inhibits 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo(a)pyrene-induced lung tumorigenesis in A/J mice and modulates carcinogen-induced alterations in protein levels. Cancer Res 67 (2007) 6502-6511
77. Oganesian A., Hendricks J.D., Pereira C.B., Orner G.A., Bailey G.S., and Williams D.E. Potency of dietary indole-3-carbinol as a promoter of aflatoxin B1-initiated hepatocarcinogenesis: results from a 9000 animal tumor study. Carcinogenesis 20 (1999) 453-458
78. Doppalapudi R.S., Riccio E.S., Rausch L.L., et al. Evaluation of chemopreventive agents for genotoxic activity. Mutat Res 629 (2007) 148-160
79. Chang X., Tou J.C., Hong C., et al. 3,3′-Diindolylmethane inhibits angiogenesis and the growth of transplantable human breast carcinoma in athymic mice. Carcinogenesis 26 (2005) 771-778
80. Kong D., Banerjee S., Huang W., et al. Mammalian target of rapamycin repression by 3,3′-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Res 68 (2008) 1927-1934
81. Kong D., Li Y., Wang Z., Banerjee S., and Sarkar F.H. Inhibition of angiogenesis and invasion by 3,3′-diindolylmethane is mediated by the nuclear factor-kappa B downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 67 (2007) 3310-3319
82. Ali S., Banerjee S., Ahmad A., El-Rayes B.F., Philip P.A., and Sarkar F.H. Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Cancer Ther 7 (2008) 1708-1719
83. Nachshon-Kedmi M., Fares F.A., and Yannai S. Therapeutic activity of 3,3′-diindolylmethane on prostate cancer in an in vivo model. Prostate 61 (2004) 153-160
84. Reed G.A., Peterson K.S., Smith H.J., et al. A phase I study of indole-3-carbinol in women: tolerability and effects. Cancer Epidemiol Biomarkers Prev 14 (2005) 1953-1960
85. Rosen C.A., and Bryson P.C. Indole-3-carbinol for recurrent respiratory papillomatosis: long-term results. J Voice 18 (2004) 248-253
86. Reed G.A., Sunega J.M., Sullivan D.K., et al. Single-dose pharmacokinetics and tolerability of absorption-enhanced 3,3'-diindolylmethane in healthy subjects. Cancer Epidemiol Biomarkers Prev 17 (2008) 2619-2624
87. Heath EI, Heilbrun LK, Vaishampayan UN, et al. A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'-diindolylmethane) in castrate-resistant, non-metastatic, PSA relapse prostate cancer patients. 2009 Genitourinary Cancers Symposium 2009;Abstract 188.
88. Kunnumakkara A.B., Anand P., and Aggarwal B.B. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 269 (2008) 199-225
89. Bharti A.C., Donato N., Singh S., and Aggarwal B.B. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101 (2003) 1053-1062
90. Hussain A.R., Ahmed M., Al-Jomah N.A., et al. Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther 7 (2008) 3318-3329
91. Kunnumakkara A.B., Diagaradjane P., Guha S., et al. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappa B-regulated gene products. Clin Cancer Res 14 (2008) 2128-2136
92. Wang D., Veena M.S., Stevenson K., et al. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappa B by an AKT-independent pathway. Clin Cancer Res 14 (2008) 6228-6236
93. Milacic V., Banerjee S., Landis-Piwowar K.R., Sarkar F.H., Majumdar A.P., and Dou Q.P. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res 68 (2008) 7283-7292
94. Yu S., Shen G., Khor T.O., Kim J.H., and Kong A.N. Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol Cancer Ther 7 (2008) 2609-2620
95. Weir N.M., Selvendiran K., Kutala V.K., et al. Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther 6 (2007) 178-184
96. Kumar A.P., Garcia G.E., Ghosh R., Rajnarayanan R.V., Alworth W.L., and Slaga T.J. 4-Hydroxy-3-methoxybenzoic acid methyl ester: a curcumin derivative targets Akt/NF kappa B cell survival signaling pathway: potential for prostate cancer management. Neoplasia 5 (2003) 255-266
97. Squires M.S., Hudson E.A., Howells L., et al. Relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase/protein kinase B (PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells. Biochem Pharmacol 65 (2003) 361-376
98. Woo J.H., Kim Y.H., Choi Y.J., et al. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 24 (2003) 1199-1208
99. Anand P., Thomas S.G., Kunnumakkara A.B., et al. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 76 (2008) 1590-1611
100. Sharma R.A., Euden S.A., Platton S.L., et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10 (2004) 6847-6854
101. Garcea G., Berry D.P., Jones D.J., et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14 (2005) 120-125
102. Garcea G., Jones D.J., Singh R., et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 90 (2004) 1011-1015
103. Padhye S, Yang H, Jamadar A, et al. New Difluoro Knoevenagel Condensates of Curcumin, Their Schiff Bases and Copper Complexes as Proteasome Inhibitors and Apoptosis Inducers in Cancer Cells. Pharm Res 2009.
104. Kim G.Y., Kim K.H., Lee S.H., et al. Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-kappa B as potential targets. J Immunol 174 (2005) 8116-8124
105. Salh B., Assi K., Templeman V., et al. Curcumin attenuates DNB-induced murine colitis. Am J Physiol Gastrointest Liver Physiol 285 (2003) G235-G243
106. Yan C., Jamaluddin M.S., Aggarwal B., Myers J., and Boyd D.D. Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin. Mol Cancer Ther 4 (2005) 233-241
107. Ryu M.J., Cho M., Song J.Y., et al. Natural derivatives of curcumin attenuate the Wnt/beta-catenin pathway through down-regulation of the transcriptional coactivator p300. Biochem Biophys Res Commun 377 (2008) 1304-1308
108. Jaiswal A.S., Marlow B.P., Gupta N., and Narayan S. Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 21 (2002) 8414-8427
109. Nakamura K., Yasunaga Y., Segawa T., et al. Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. Int J Oncol 21 (2002) 825-830
110. Ohtsu H., Xiao Z., and Ishida J. Et al. Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J Med Chem 45 (2002) 5037-5042
111. Huang A.C., Lin S.Y., Su C.C., et al. Effects of curcumin on N-bis(2-hydroxypropyl) nitrosamine (DHPN)-induced lung and liver tumorigenesis in BALB/c mice in vivo. In vivo 22 (2008) 781-785
112. Li N., Chen X., Liao J., et al. Inhibition of 7, 12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamsters by tea and curcumin. Carcinogenesis 23 (2002) 1307-1313
113. Kunnumakkara A.B., Guha S., Krishnan S., Diagaradjane P., Gelovani J., and Aggarwal B.B. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappa B-regulated gene products. Cancer Res 67 (2007) 3853-3861
114. Cruz-Correa M., Shoskes D.A., Sanchez P., et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 4 (2006) 1035-1038
115. Cheng A.L., Hsu C.H., Lin J.K., et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21 (2001) 2895-2900